Aclaris Therapeutics, Inc (ACRS) - מקדם חוב לטווח ארוך להון

The biotechnology sector for the therapy of dermatological and immune pathologies is currently growing rapidly, fueling interest in Aclaris Therapeutics (ACRS) assets. Aclaris Therapeutics (ACRS) is minimizing risks by developing a portfolio of drugs for rheumatology and skin. The indicator stands at 0.01. This price chart on GURU.Markets confirms the high potential of the brand, whose small-molecule anti-inflammatory developments are trusted by industry specialists.

This ratio determines the share of long-term liabilities within the equity structure, allowing for an assessment of financial stability and the business's degree of dependence on borrowed funds. Analyzing long-term debt-to-equity is critically important for Aclaris Therapeutics (ACRS), as colossal R&D expenditures and patent disputes require a significant liquidity buffer to mitigate clinical trial risks.